Our co-investigator of this study previously performed an original study in Hong Kong to evaluate the risks of cancer among patients with DM-II on Metformin dual therapy with inadequate control and were synchronously administered with third-line glucose-reducing medications, namely DPP4-inhibitors, insulin or thiazolidinediones [19]. The gene discussed is INS; the disease is diabetes mellitus.